Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Out-Licenses Emerging Marking Rights for Avastin Biosimilar to Cipla

publication date: Jan 14, 2019

Bio-Thera Solutions, a Guangzhou biopharma, out-licensed marketing rights for its Avastin biosimilar to India's Cipla (BSE: 500087) in certain emerging markets. The agreement is a rare China-Indian biopharma agreement. Cipla was chosen because it has a strong presence in emerging markets. Bio-Thera’s BAT-1706 is currently being tested in a global Phase III study as a first-line therapy for advanced non-squamous non-small cell lung cancer. The company expects to file for approval of the biosimilar in China, the US and Europe in 2020. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital